“…The unique capacity of PRN to interfere with microtubule assembly via α-tubulin binding, coupled with its antitumor properties, have stimulated the search for more potent analogues. Over the past 20 years, synthetic approaches have been explored to produce PRN via different chemical routes [ 18 , 19 , 20 , 21 , 22 ] and to generate simplified PRN derivatives with improved pharmacological properties and metabolic stability [ 23 , 24 , 25 , 26 , 27 , 28 , 29 ]. Hybrid molecules combining the scaffold of PRN with other MTAs, such as combretastatin and colchicine, have been designed as well [ 30 , 31 , 32 ].…”